Model-based evaluation of diabetic foot prevention strategies in Austria

Health Care Management Science

Volumn 8, Issue 4, 2005, Pages 253-265

  Rauner, Marion S ^a   Heidenberger, Kurt ^a   Pesendorfer, Eva Maria ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cost effectiveness analysis; Diabetes mellitus; Diabetic foot prevention; Markov model; Monte Carlo simulation

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRIA; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; MONTE CARLO METHOD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICS;

ADULT; AGED; AUSTRIA; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC FOOT; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 29144447853     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-005-4136-6     Document Type: Article

References (69)

1. A. Amos, D. McCarty, and P. Zimmet, The rising global burden of diabetes and its complications: Estimates and projections to year 2010, Diabetic Medicine 14 (1997) S1-S85.
2. J. Apelqvist, G. Ragnarson-Tennvall, J. Larsson, et al., Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting, Foot Ankle International 16(7) (1995) 388-394.
3. J. Apelqvist, G. Ragnarson-Tennvall, U. Persson, et al., Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation, Journal of Internal Medicine 235(5) (1994) 463-471.
4. D.G. Armstrong and L.A. Lavery, Diabetic foot ulcers: Prevention, diagnosis and classification, American Family Physician 57(6) (1998) 1325-1332.
5. A. Bagust, P. Hopkinson, W. Maier, and C. Currie, An economic model of the long-term helath care burden of type II diabetes, Diabetologia 44 (2001) 2140-2155.
6. M. Berger, Diabetes Mellitus (Urban und Schwarzenberg, Munich, 1995).
7. B.O. Boehm, K.-D. Palitzsch, C. Rosak, et al., Klinische Diabetologie (Springer Verlag, Berlin, 2001).
8. A.J. Boulton, Lowering the risk of neuropathy, foot ulcers and amputations, Diabetic Medicine 15 (1998) S57-S59.
9. S.C. Brailsford, R. Davies, C. Canning, and P.J. Roderick, Evaluating screening policies for the early detection of retinopathy in patients with non-insulin dependent diabetes, Health Care Management Science 1(2) (1998) 115-124.
10. M. Brandle, H. Zhou, B. Smith, et al., The direct medical costs of type 2 diabetes, Diabetes Care 26(8) (2003) 2300-2304.
11. G. Bronneberg and I. Rottenhofer, Schulungsmodelle fuer Typ-II-Diabetes (Oesterreichisches Bundesinstitut für Gesundheitswesen, Vienna, 1999).
12. A. Brugger, Betreuungskonzepte für Patienten mit Typ-2-Diabetes in Oesterreich, Diabetes Forum (1) (2002) 40ff.
13. J. Caro, A. Ward, and J. O'Brien, Lifetime costs of complications resulting from type 2 diabetes in the U.S., Diabetes Care 25(3) (2002) 476-481.
14. T. Chen, M. Yen, and T. Tung, A computer simulation model for cost-effectiveness analysis of mass screening fot type 2 diabetes mellitus, Diabetes Research and Clinical Practice 54 (2001) S37-S42.
15. D. Cheta, Preventing Diabetes: Theory, Practice and New Approaches (John Wiley & Sons Ltd., Chichester, 1999).
16. R.C. Eastman, J.C. Javitt, W.H. Herman, et al., Model of complications of NIDDM. I. Model construction and assumptions, Diabetes Care 20(5) (1997) 725-734.
17. M.H. Eckman, S. Greenfield, W.C. Mackey, et al., Foot infections in diabetic patients: Decision and cost-effectiveness analyses, Journal of the American Medical Association 273(9) (1995) 712-720.
18. J.M. Ekoé, R. Williams, and P. Zimmet, Introduction, in: The Epidemiology of Diabetes Mellitus - An International Perspective, eds. J.M. Ekoé, P. Zimmet and R. Williams (John Wiley & Sons Ltd., Chichester, 2001).
19. J.M. Ekoé and P. Zimmet, The clinical syndrome and the biochemical definition, in: The Epidemiology of Diabetes Mellitus - An International Perspective, eds. J.M. Ekoé, P. Zimmet, and R. Williams (John Wiley & Sons Ltd., Chichester, 2001).
20. R. Furlan, E. Butti, S. Pluchino, and G. Martino, Gene therapy for autoimmune diseases, Current Opinion in Molecular Therapeutics 6(5) (2004) 525-536.
21. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein, Cost-Effectiveness in Health and Medicine (Oxford University Press, N.Y., 1996).
22. J.D. Graham, P.S. Corso, J.M. Morris, et al., Evaluating the cost-effectiveness of clinical and public health measures, Annual Review of Public Health 19(1998) 125-152.
23. A. Green, E. Gale, and C. Patterson, Incidence of childhood-onset insulin-dependent diabetes mellitus: The EURODIAB ACE study, Lancet 339 (1992) 905-909.
24. M. Harris, W. Hadden, W. Knowler, and P. Bennett, Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 years, Diabetes 36(1987) 523-534.
25. W.M. Hart, C. Espinosa, and J. Rovira, A simulation model of the cost of the incidence of IDDM in Spain, Diabetologia 40(3) (1997) 311-318.
26. P. Hogan, T. Dall, and P. Nikolov, Economic costs of diabetes in the US in 2002, Diabetes Care 26(3) (2003) 917-932.
27. International Working Group on the Diabetic Foot and http://www.diabetic- foot-consensus.com, International consensus on the diabetic foot, (access 27-05-2003).
28. International Diabetes Foundation and http://www.idf.org/e-atlas, E-Atlas, (access 22-07-2003).
29. W. Jeffcoate and R. Macfarlane, The Diabetic Foot: An Illustrated Guide to Management (Chapman & Hall Medical, London, 1995).
30. W.J. Jeffcoate and K.G. Harding, Diabetic foot ulcers, Lancet 361(9368) (2003) 1545-1551.
31. D. Klonoff and D. Schwartz, An economic analysis of interventions for diabetes, Diabetes Care 23(3) (2000) 390-404.
32. K.M. Kuntz and M.C. Weinstein, Modelling in economic evaluation, in: Economic Evaluation in Health Care: Merging Theory With Practice, eds. M. Drummond and A. McGuire (Oxford University Press, Oxford, 2001).
33. L.A. Lavery, D.G. Armstrong, and L.B. Harkless, Classification of diabetic foot wounds, Ostomy Wound Management 43(2) (1997) 44-48.
34. C. Leventan, Diabetes prevention: How about now? Clinical Diabetes 19(1) (2001) 34.
35. A. Liebl, A. Spannheimer, U. Reitberger, et al., Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study, Medizinische Klinink 97(12) (2002) 713-719.
36. J.M. Malone, M. Snyder, G. Anderson, et al., Prevention of amputation by diabetic education, American Journal of Surgery 158(6) (1989) 520-523.
37. H. Mehnert, Typ-2-Diabetes: Pathogenese, Diagnostik, Therapie, Folgeschaeden (Medikon Verlag, Munich, 2000).
38. A. Mokdad, E. Ford, B. Bowman, et al., Diabetes trends in the US: 1990-1998, Diabetes Care 23 (2000) 1278-1283.
39. A. Mokdad, E. Ford, B. Bowman, et al., The continuing increase in diabetes in the US, Diabetes Care 24 (2001) 412.
40. A.H. Mokdad, M.K. Serdula, W.H. Dietz, et al., The spread of the obesity epidemic in the United States - 1991-1998, Journal of the American Medical Association 282(1999) 1519-1522.
41. S. Moss, R. Klein, and B. Klein, Long-term incidence of lower-extremity amputations in a diabetic population, Archives of Family Medicine 5(7) (1996) 391-398.
42. I. Muhlhauser, M. Sulzer, and M. Berger, Quality assessment of diabetes care according to the recommendations of the St. Vincent Declaration: A population-based study in a rural area of Austria, Diabetologia 35(5) (1992) 429-435.
43. K. Narayan, J. Boyle, T. Thompson, et al., Lifetime risk for diabetes mellitus in the United States, Journal of the American Medical Association 290(14) (2003) 1884-1890.
44. K. Narayan, E. Gregg, A. Fagot-Campagna, M. Engelgau, et al., Diabetes: A common, growing, serious, costly, and potentially preventable public health problem, Diabetes Research and Clinical Practice 50 (2000) S77-S84.
45. J.A. O'Brien, A.R. Patrick, and J. Caro, Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000, Clinical Therapy 25(3) (2003) 1017-1038.
46. Oesterreichische Akademie der Wissenschaften, Diabetisches Fuß-Syndrom, Health Technology Assessment Newsletter: Evaluation medizinischer Interventionen (5) (2002) 3.
47. D.A. Ollendorf, J.G. Kotsanos, W.J. Wishner, et al., Potential economic benefits of lower-extremity amputation prevention strategies in diabetes, Diabetes Care 21(8) (1998) 1240-1245.
48. M.M. Ortegon, W.K. Redekop, and L.W. Niessen, Cost-effectiveness of prevention and treatment of the diabetic foot, Diabetes Care 27(4) (2004) 901-907.
49. D.K. Owens, Interpretation of cost-effectiveness analyses, Journal of General Internal Medicine 13(10) (1998) 716-717.
50. E.-M. Pesendorfer, Oekonomische Evaluation von Praeventionsmaß nahmen zur Verminderung von Spaetkomplikationen des Diabetes Mellitus, Master's thesis, University of Vienna, Vienna (2003).
51. T.R. Pieber, A. Holler, and G.A. Brunner, et al., Diabetesbetreuung in Oesterreich 5 Jahre nach der St. Vincent-Erklaerung, Wiener Klinische Wochenschrift 107(15) (1995) 451-156.
52. G. Ragnarson-Tennvall and J. Apelqvist, Prevention of diabetes-related foot ulcers and amputations: A cost-utility analysis based on Markov model simulations, Diabetologia 44(11) (2001) 2077-2087.
53. M.S. Rauner, K. Heidenberger, and E.-M. Pesendorfer, Using a Markov model to evaluate the cost-effectiveness of diabetic foot prevention strategies in Austria, in: Western Multiconference, Proceedings of the International Conference on Health Sciences Simulation, January 18-22, 2004, San Diego, CA, eds. J. Anderson and M. Katzper (The Society of Simulation International, San Diego, CA, 2004), 63-68.
54. G.E. Reiber, Diabetic foot care, Diabetes Care 15(1992) S29-S31.
55. G.E. Reiber, R.E. Pecoraro, and T.D. Koepsell, Risk factors for amputation in patients with diabetes mellitus. A case-control study, Annals of Internal Medicine 117(2) (1992) 97-105.
56. F.A. Sonnenberg and J.R. Beck, Markov models in medical decision making: A practical guide, Medical Decision Making 13(4) (1993) 322-338.
57. M. Spraul, Praevention des diabetischen Fußsyndroms, Der Internist 40 (1999) 1056-1066.
58. E. Standl, Zur Epidemiologie des diabetischen Fußsyndroms, Diabetes und Stoffwechsel 9 (2000) 339-342.
59. Statistik Austria, Gesundheitszustand und Konsum Medizinischer Leistungen (Verlag Oesterreich GmbH, Vienna, 2002).
60. T.O. Tengs, M.E. Adams, J.S. Pliskin, et al., Five-hundred life-saving interventions and their cost-effectiveness, Risk Analysis 15(3) (1995) 369-390.
61. TreeAge Software Inc., Healthcare User's Manual Data 4.0 (TreeAge Software Inc, Williamstown, MA, 2001).
62. J. Tuomilehto, J. Lindstrom, and J. Eriksson, et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, New England Journal of Medicine 344(18) (2001) 1343-1350.
63. W.H. van Houtum, L.A. Lavery, and L.B. Harkless, The costs of diabetes-related lower extremity amputations in the Netherlands, Diabetic Medicine 12(9) (1995) 777-781.
64. R. Waneck, Nationaler Oesterreichischer Gesundheitsplan (Federal Ministry of Health and Women, Vienna, 2002).
65. R. Williams, Ascertainment, prevalance, incidence and temporal trends, in: The Epidemiology of Diabetes Mellitus, eds. J.M. Ekoé, P. Zimmet, and R. Williams (John Wiley & Sons Ltd., Chichester, 2001).
66. World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, (WHO, Geneva, 1999).
67. World Health Organization and http://www.who.int, Diabetes Mellitus, (access 29-04-2005).
68. World Health Organization International Diabetes Federation, Diabetes Care and Research in Europe: The St. Vincent Declaration Action Programme, (WHO, Geneva, 1992).
69. M.J. Young and A.J.M. Boulton, The diabetic foot, in: Diabetes in Old Age, eds. A.J. Sinclair and P. Finucane (John Wiley & Sons, Ltd., Chichester, 2001).